- Home
- CASS vs SVRA Comparison
CASS vs SVRA Comparison
Compare CASS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- SVRA
- Stock Information
- Founded
- CASS 1906
- SVRA N/A
- Country
- CASS United States
- SVRA United States
- Employees
- CASS 1209
- SVRA N/A
- Industry
- CASS Business Services
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- SVRA Health Care
- Exchange
- CASS Nasdaq
- SVRA Nasdaq
- Market Cap
- CASS 535.4M
- SVRA 540.6M
- IPO Year
- CASS 1996
- SVRA N/A
- Fundamental
- Price
- CASS $39.46
- SVRA $2.72
- Analyst Decision
- CASS Buy
- SVRA Buy
- Analyst Count
- CASS 1
- SVRA 7
- Target Price
- CASS $45.00
- SVRA $9.86
- AVG Volume (30 Days)
- CASS 47.7K
- SVRA 1.0M
- Earning Date
- CASS 01-23-2025
- SVRA 03-06-2025
- Dividend Yield
- CASS 3.14%
- SVRA N/A
- EPS Growth
- CASS N/A
- SVRA N/A
- EPS
- CASS 1.68
- SVRA N/A
- Revenue
- CASS $220,027,000.00
- SVRA N/A
- Revenue This Year
- CASS N/A
- SVRA N/A
- Revenue Next Year
- CASS $5.32
- SVRA N/A
- P/E Ratio
- CASS $23.53
- SVRA N/A
- Revenue Growth
- CASS 4.97
- SVRA N/A
- 52 Week Low
- CASS $37.99
- SVRA $2.60
- 52 Week High
- CASS $50.25
- SVRA $5.70
- Technical
- Relative Strength Index (RSI)
- CASS 36.44
- SVRA 30.94
- Support Level
- CASS $38.01
- SVRA $2.60
- Resistance Level
- CASS $41.71
- SVRA $3.13
- Average True Range (ATR)
- CASS 1.07
- SVRA 0.15
- MACD
- CASS -0.16
- SVRA -0.03
- Stochastic Oscillator
- CASS 34.12
- SVRA 16.67
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.